New Day Diagnostics LLC is pleased to announce that it has entered into an asset purchase agreement with Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), a molecular diagnostics company focused on blood testing for the early detection of cancer. This agreement is the successful result of negotiations previously disclosed by Epigenomics AG in their ad hoc announcement dated June 12, 2023.
Today’s announcement comes on the heels of New Day Diagnostics’ recent merger with EDP Biotech Corp. and furthers the company’s mission of expanding the availability of cost-effective early-detection products to patients.
Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics’ portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.
“We began a mission nearly two decades ago to drive accessibility of cost-effective early detection products. The addition of Epi proColon expands the company portfolio to include a much needed non-invasive CRC screening test that is both affordable and convenient,” said Eric Mayer, CEO of New Day Diagnostics LLC. “And we are excited to explore additional possibilities for the methylated DNA biomarker in improving patient outcomes for other indications.”
The commercialization of Epi proColon “Next-Gen” is one of the expected outcomes of the sale of Epigenomics assets to New Day Diagnostics. This, coupled with an increased likelihood of reimbursement by CMS, would allow the company to make an important contribution to reducing cancer disease and deaths.
Jens Ravens, Executive of Epigenomics said, “There is a great deal of strategic alignment between our companies. Because of this, I feel confident that the best of our products and biomarker technology will move into the next chapter of bringing a blood-based colorectal cancer diagnostic to the market that is both affordable and accessible.”
New Day Diagnostics is committed to empowering people around the world to manage their healthcare and live healthier lives through accessible diagnostic testing. The company is focused on innovating in areas that improve affordability as well as convenience for people around the world. New Day Diagnostics specializes in designing, developing, and bring to market diagnostic tests, and the Epigenomics assets would further enhance the company’s ability to develop and commercialize diagnostic tests for earlier intervention and improved patient outcomes.
TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics’ legal advisors.
bullet list
numbered list
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
